capecitabine + gemcitabine + 5-fluorouracil

Capecitabine, gemcitabine, and 5-fluorouracil are antimetabolite chemotherapy agents commonly used in the treatment of various cancers, including pancreatic cancer. Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) in tumor tissues by thymidine phosphorylase. Both capecitabine (via its active metabolite) and direct administration of 5-FU inhibit DNA synthesis by targeting thymidylate synthase, leading to disruption of DNA replication and RNA function. Gemcitabine is a nucleoside analog that inhibits DNA synthesis through incorporation into DNA strands and inhibition of ribonucleotide reductase. These drugs are often combined due to their complementary mechanisms and non-overlapping toxicity profiles. The combination regimens have been evaluated primarily for advanced pancreatic cancer but also in other solid tumors[1][2][3][4][8].

Other names

GemCap (for the combination of gemcitabine and capecitabine)5-FU (common abbreviation for 5-fluorouracil)